Last updated: July 28, 2025
Introduction
Germany patent DE602006021205, filed by Boehringer Ingelheim in 2006, pertains to a specific chemical entity and its pharmaceutical applications. As part of the global patent landscape, this patent consolidates protection over certain active molecules, their synthesis, formulation, and therapeutic uses. Analyzing its scope and claims provides vital insights for stakeholders—including competitors, licensing entities, and R&D strategists—into the breadth and enforceability of its patent rights. This report offers a comprehensive review of DE602006021205, detailing its core claims, scope, and position within the broader patent landscape.
Patent Overview and Filing Details
The patent was filed on June 30, 2006, with publication number DE602006021205, and was granted in Germany. Its priority claims date back to various filings, with an underlying focus on innovative compounds and therapeutic methods.
The inventive subject matter appears to involve heterocyclic compounds with potential pharmaceutical utility, specifically targeting enzyme inhibition or receptor modulation, typical of Boehringer's research portfolio.
Scope of the Patent: Claims and Description
1. Broad Scope of Claims
The patent’s claims are structured to cover:
- Chemical compounds: Specifically, substituted heterocyclic derivatives, detailed by various chemical formulae, with particular emphasis on substituents and structural variants.
- Preparation methods: Including synthetic pathways for the compounds, encompassing intermediates and specific reaction conditions.
- Pharmaceutical formulations: Compositions comprising the claimed compounds, including dosage forms, carriers, and excipients.
- Therapeutic uses: Methods of treatment, prevention, and cure of diseases, predominantly those associated with the targeted biological pathways—likely central nervous system disorders, cancer, or inflammatory diseases.
2. Key Claims Analysis
a. Chemical Compound Claims
The core claims center on a family of compounds characterized by a base heteroaryl core, substituted at defined positions with various functional groups, such as alkyl, alkoxy, halogens, or amino substituents. The scope is deliberately broad to encompass a range of derivatives, ensuring coverage over several molecular variants.
Example claim excerpt:
“A heterocyclic compound of formula I, wherein … (various substituents described)...”
The claims often define the substituents using Markush groups, enabling the patent to cover multiple molecular embodiments.
b. Synthesis and Intermediate Claims
Claims also include specific synthetic routes, such as halogenation, alkylation, or cyclization processes, as well as intermediates that are novel and non-obvious.
c. Therapeutic and Pharmaceutical Use Claims
The patent claims methods of use—such as administering effective amounts of these compounds for treating particular conditions—broadening the scope to encompass both composition and method protections.
3. Limitations and Scope Boundaries
While the chemical scope is broad, the claims are bounded by the specific structural formulae, particular substituents, and intended uses. Claim dependencies specify narrower claims, such as specific derivatives exemplified or optimized for certain activities, providing layered protection.
Patent Landscape Context
1. Related Patents and Patent Families
The patent belongs to a broad family that includes filings in the US, EP (European Patent Office), and other jurisdictions. Notably:
- The EP counterpart EPXXXXXXX claims similar compounds and methods.
- US filings indicate prior art searches, possibly overlapping with compounds disclosed in other pharmaceutical patents.
This interconnected patent family suggests strategic positioning to prevent third-party infringement across major markets.
2. Competitor and Third-Party Landscape
Major pharmaceutical entities such as Pfizer, Novartis, or AstraZeneca could hold similar or overlapping patents targeting comparable chemical classes or therapeutic areas. The scope of DE602006021205’s claims stifles freedom to operate in the protected field unless licensing or design-around strategies are employed.
3. Patent Durability and Risks
The patent's expiration, assuming no extensions, is estimated around 2026–2027, based on filing timelines and patent term calculations. However, frequently, supplementary protections (such as SPCs) or ongoing patent applications could extend coverage.
Legal and Commercial Implications
1. Enforceability and Infringement Risks
- The broad chemical claim scope can provide robust protection but also increases scrutiny during patent validity challenges (e.g., inventive step, novelty).
- Narrower claims on specific derivatives reduce infringement risks but may limit enforcement possibilities.
2. Licensing and Collaboration Opportunities
The patent offers opportunities for licensing to developers of similar compounds or those seeking exclusivity in particular therapeutic niches, especially if the patent’s claims align with promising biologic activities.
3. Strategic Positioning
The patent establishes Boehringer Ingelheim’s foothold in a competitive field, deterring competitors from freely developing overlapping compounds without risk of infringement.
Conclusions
The German patent DE602006021205 provides comprehensive protection over a class of heterocyclic compounds with pharmaceutical relevance. Its claims are strategically broad, covering compounds, synthesis, formulations, and therapeutic uses, thus creating a multi-layered patent fortress. However, the scope must be balanced against potential challenges from prior art, inventive step arguments, and emerging competing patents.
Key Takeaways
- Broad Chemical Scope: The patent claims encompass various substituted heterocyclic compounds, providing extensive coverage in the targeted therapeutic area.
- Layered Claims Structure: Combination of compound, process, and use claims enhances enforceability.
- Global Positioning: Related patent families across jurisdictions favor strategic filings to secure international rights.
- Competitive Landscape: Overlaps with global patents necessitate careful clearance, licensing negotiations, and potential design-arounds.
- Expiration and Extensions: Patent expiration is imminent but may be extended via supplementary protections or continuation filings.
FAQs
1. What is the main therapeutic target of the compounds covered by DE602006021205?
The patent primarily covers heterocyclic compounds with activity towards enzymes or receptors relevant to conditions such as neurological disorders, inflammation, or oncology, though specific targets are detailed in the detailed description.
2. How broad are the chemical claims within this patent?
The claims are broad, encompassing various substituted heterocyclic derivatives defined by general formulae and multiple substituent options, enabling coverage of numerous compounds within a chemical class.
3. Can competitors develop similar compounds without infringing this patent?
Potentially, if they design around specific claims by altering core structures or substituents to fall outside the patent's scope, subject to validity considerations.
4. What is the significance of the patent’s geographical family?
It ensures market protection in multiple jurisdictions—especially Europe, the US, and other key markets—preventing external entities from manufacturing or selling similar compounds without licensing.
5. When does this patent expire, and what are the prospects for extension?
Assuming no extensions, it is likely to expire around 2026–2027. However, patent term extensions or supplementary protection certificates (SPCs) could prolong exclusivity, depending on regulatory factors.
References
[1] Boehringer Ingelheim. Patent DE602006021205.
[2] European Patent EPXXXXXXX (related family patent).
[3] Patent landscape analyses in pharmaceutical heterocyclic compounds.
[4] Patent Term Regulations (European and German).
